MORRISVILLE, N.C., Aug. 8, 2016 /PRNewswire/ -- TearScience, a privately held medical device company and manufacturer of LipiScan™, LipiView® II and LipiFlow®, today announced the addition of Edward J. Holland, MD, to its Board of Directors.
"TearScience has shifted the perception of dry eye among eye care professionals (ECP's) to a proactive approach. TearScience technology offers an unparalleled ability to visualize and image the meibomian glands. TearScience technology also treats Meibomian Gland Dysfunction (MGD), an important and underappreciated cause of dry eye. I have worked closely with the company as the technology and market have evolved and am excited to be a part of the bright future of TearScience," Dr. Holland said.
Dr. Holland was awarded the Life Achievement Honor Award at the 2012 American Academy of Ophthalmology Annual Meeting and has been listed in the "Best Doctors in America" on numerous occasions. He has written over 200 articles in peer-reviewed journals and has received worldwide recognition for his knowledge and expertise.
"Dr. Holland is a leader in the field of Cornea and Ocular Surface Health; as a respected expert, his guidance will help shape how we further the understanding of MGD among ECPs. This is the first time that Dr. Holland has joined a commercial Board of Directors and we are honored to have him advise us in creating greater value for eye care," said Joseph Boorady, CEO.
Appreciation of the chronic, obstructive and progressive nature of MGD has increased in recent years as research has revealed the importance of meibomian gland health for overall ocular surface health. LipiScan™ and LipiView II® improve the ability of ECPs to image and view meibomian gland structure with unmatched clarity. LipiFlow® treats the MGD, the most common underlying cause of Dry Eye Disease, by applying heat to the inner lid and simultaneous pulsatile pressure to the outer lid. A review of 31 sponsored and unsponsored peer-reviewed studies demonstrated that a single LipiFlow treatment typically improves mean meibomian gland secretions while at the same time reducing mean patient-reported symptom scores over sustained periods.1 Studies also showed a low rate of transient, non-serious device-related adverse events. None of the studies reported any unanticipated or serious device-related adverse events.1
TearScience, a medical device company, has pioneered technologies and leads innovation to vastly improve evaluation of meibomian glands and treatment of meibomian gland dysfunction (MGD). A progressive, obstructive disease and root cause of dry eye, MGD is distinguished by loss of function and structure of tear oil (meibomian) glands. MGD affects approximately 86% of the millions of dry eye sufferers worldwide and is highly prevalent in the general ophthalmic population. LipiView II and new LipiScan with Dynamic Meibomian Imaging™ (DMI) distinctively images meibomian gland structure. The Korb Meibomian Gland Evaluator™ assists physicians to reproducibly assess gland function. LipiFlow uses Vectored Thermal Pulse™ (VTP) technology to precisely direct treatment from the inner-lid and has received clearance by the US Food and Drug Administration for use in patients with MGD. Sponsored and unsponsored multicenter, randomized, controlled clinical studies of LipiFlow demonstrate its safety and sustained effectiveness. For additional information on how TearScience improves evaluation of MGD, meibomian gland function, and symptoms for patients with MGD worldwide, visit www.TearScience.com.
1. Blackie, C. A., Carlson, A. N., & Korb, D. R. (2015). Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation. Current Opinion in Ophthalmology, 26(4), 306-313. Retrieved from http://tearscience.com/en/wp-content/uploads/455117X_21184-0187.pdf
Pascale Communications, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tearscience-names-edward-j-holland-md-to-board-of-directors-300310382.html